Which Factors Will Push The Neonatal Respiratory Distress Syndrome Treatment Market To Achieve $1.39 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Neonatal Respiratory Distress Syndrome Treatment Market Be Worth By 2029?
In recent years, the market size for neonatal respiratory distress syndrome treatment has seen robust growth. It is expected to expand from a valuation of $0.96 billion in 2024 to $1.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.0%. The historical period growth is due to factors such as increased fluid accumulation and permeability within the alveoli, amplification in alveolar-capillary permeability, a rise in the use of mechanical ventilation, advancing consciousness among health care providers and parents regarding the significance of neonatal care, and the escalation in healthcare investments.
The market for neonatal respiratory distress syndrome treatment is projected to experience significant expansion in the coming years. The market value is set to reach $1.39 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The expected growth during the forecast period is due to factors such as growing inclination towards accessories and consumables, increased NICU admissions, a surge in demand for personalized medicine, rise in premature births, and heightened research and development activities. Key trends forecasted in this timeframe include automation in neonatal intensive care units (NICUs), the application of artificial intelligence (AI), advancements in neonatal care technology, innovations in surfactant therapy, and the introduction of advanced ventilator technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20899&type=smp
Which Key Factors Are Fueling Growth In The Neonatal Respiratory Distress Syndrome Treatment Market?
The neonatal respiratory distress syndrome treatment market is anticipated to grow owing to an increase in premature birth occurrences. Premature or preterm babies are those born before the 37th week of pregnancy, and those born before the 32nd week face the most serious health complications, as an average pregnancy lasts approximately 40 weeks. An upward trend in premature births is seen due to reasons like later maternal age, multiple pregnancies, varied health conditions, lifestyle decisions, utilization of fertility treatments, infections, and environmental factors. Neonatal respiratory distress syndrome (NRDS) treatment is typically necessary for preterm infants as their lungs are underdeveloped and there is inadequate surfactant production. This treatment aids in enhancing lung function, stabilizing breathing, and minimizing the likelihood of respiratory failure in premature infants. For example, Tommy’s, a UK-based charity, reported that the rate of premature live births in England and Wales climbed to 7.9% in 2022 from 7.5% in 2021, marking the second year in a row of an increase in premature births. Over 53,000 babies were prematurely born in 2022. Therefore, the uptick in premature births prevalence is fueling the growth of the neonatal respiratory distress syndrome treatment market.
Which Segmentation Factors Are Critical In The Neonatal Respiratory Distress Syndrome Treatment Market Analysis?
The neonatal respiratory distress syndrome treatmentmarket covered in this report is segmented –
1) By Therapy: Oxygen Therapy; Surfactant Therapy
2) By Route Of Administration: Parenteral; Inhalation; Other Routes Of Administration
3) By End User: Hospitals; Sub-Acute Facilities; Home Care; Retail Pharmacies
Subsegments:
1) By Oxygen Therapy: Conventional Oxygen Therapy; High-Flow Nasal Cannula (HFNC) Oxygen Therapy; Continuous Positive Airway Pressure (CPAP) Oxygen Therapy; Invasive Mechanical Ventilation With Oxygen Therapy
2) By Surfactant Therapy: Natural Surfactants; Synthetic Surfactants; Combined Surfactant Therapy (Natural + Synthetic); Prophylactic Surfactant Therapy; Rescue Surfactant Therapy
How Are Global Trends Impacting The Development Of The Neonatal Respiratory Distress Syndrome Treatment Market?
Key players in the neonatal respiratory distress syndrome treatment market are focusing on the innovation of high-tech solutions such as nitric oxide generators to boost oxygen levels, reduce respiratory problems, and provide non-invasive treatment for newborns with hypoxic respiratory failure. Nitric oxide generators are medicinal equipment that produce and supply nitric oxide gas, frequently used for addressing respiratory conditions by enhancing oxygenation and reducing pulmonary hypertension, particularly among neonates and severely sick patients. For example, in June 2022, Beyond Air Inc., a U.S. medical device and biopharmaceutical firm, earned FDA approval for LungFit PH. This ground-breaking nitric oxide generator is tailored to assist term and near-term newborns suffering from hypoxic respiratory failure, including persistent pulmonary hypertension of the newborn (PPHN). The device leverages Beyond Air’s proprietary Ionizer technology to produce nitric oxide from surrounding air on demand, ensuring a continuous supply without worrying about dosage or flow, and it uses a low-power compressor to ionize nitrogen and oxygen, thereby reducing the production of nitrogen dioxide (NO2) which is then efficiently eliminated by a smart filter.
Which Players Are Shaping The Competitive Landscape Of The Neonatal Respiratory Distress Syndrome Treatment Market?
Major companies operating in the neonatal respiratory distress syndrome treatment market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Medtronic Plc, Medline Industries, Becton Dickinson, Stryker Corporation, GE Healthcare, Koninklijke Philips NV, ResMed Inc., Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, ICU Medical Inc., Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Aerogen Pharma Corp., Windtree Therapeutics Inc., Discovery Laboratories Inc., Lyomark Pharma GmbH
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Neonatal Respiratory Distress Syndrome Treatment Market?
North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neonatal respiratory distress syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20899&type=smp
Browse Through More Reports Similar to the Global Neonatal Respiratory Distress Syndrome Treatment Market 2025, By The Business Research Company
Fetal And Neonatal Monitoring Devices Global Market Report 2025
Neonatal Infant Care Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/neonatal-infant-care-global-market-report
Pediatric And Neonatal Testing Kit Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
